Code No. | D060-3 | |
Anti-RCAS1 (Human) mAb | ||
Price | ¥52,800 | |
Size | 100 µL (1 mg/mL) | |
Availability (in Japan) | 1-9
(In Japan at 00:05, Apr 26, 2024 in JST) |
|
Clonality | Monoclonal | |
Clone | 22-1-1 | |
Isotype (Immunized Animal) |
Mouse IgM | |
Applications | FCM 1-5 µg/mL (final concentration) IC 1-5 µg/mL IH* reported. (PMID: 15904507 / 17849467 / 24167369) |
|
Immunogen (Antigen) |
Human uterine cervical adenocarcinoma cells | |
Reactivity [Gene ID] | Human[9166] |
|
Storage buffer | 1 mg/mL in PBS/50% glycerol, pH 7.2 | |
Storage temp. | -20°C | |
Conjugate | Unlabeled | |
Manufacturer | MBL | |
Alternative names | EBAG9, EB9, PDAF | |
Background | RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. The predicted amino acid sequence of RCAS1 (213 aa) possesses an N-terminal transmembrane region and a coiled-coil structure in the C-terminal portion, indicating that RCAS1 is a type II membrane protein able to form oligomers through the coiled-coil structure. RCAS1 revealed different expression pattern from the known tumor associated antigens such as, YH206, GA733, CA125, CEA and sialyl Lewis molecules in human tumor cell lines. Recent study indicated RCAS1 acts as a ligand for a putative receptor present on various human cells including T, B and NK cells. RCAS1 inhibited the in vitro growth of receptor-expressing cells and induced apoptosis. It was suggested that tumor cells might evade immune surveillance by expression of RCAS1. | |
Related products | D060-3H Anti-RCAS1 (Human) mAb M079-3 Mouse IgM (isotype control) |
|
Product category | Research area:Cancer Apoptosis | |
Data | ||
Citations | Flow Cytometry
Immunohistochemistry
|